GE Healthcare and Theragnostics announce global commercial partnership for late stage PSMA diagnostic for prostate cancer

Chalfont St Giles, UK (STL.News) – GE Healthcare and Theragnostics have entered into a global commercial partnership for a new Prostate-Specific Membrane Antigen (PSMA) PET/CT imaging agent. Theragnostics will lead…

The post GE Healthcare and Theragnostics announce global commercial partnership for late stage PSMA diagnostic for prostate cancer appeared first on STL.News.